RNS

RNS Number : 8525V MaxCyte, Inc. 10 July 2024   MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024   ROCKVILLE, MD , July 10, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT ), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Jul 10, 2024
RNS Number : 6718V MaxCyte, Inc. 09 July 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Change of Name of Nominated Adviser and Broker   ROCKVILLE, MD , July 9, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Jul 09, 2024
RNS Number : 8834U MaxCyte, Inc. 03 July 2024   TR-1: N otification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
Jul 03, 2024
RNS Number : 8115U MaxCyte, Inc. 02 July 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , July 2, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
Jul 02, 2024
RNS Number : 6980U MaxCyte, Inc. 02 July 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights   ROCKVILLE, MD , July 2, 2024 :   MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Jul 02, 2024
RNS Number : 2055U MaxCyte, Inc. 27 June 2024     Publication of Annual Report   ROCKVILLE, MD , June 27, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
Jun 27, 2024
RNS Number : 4058S MaxCyte, Inc. 14 June 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options and Restricted Stock Units   ROCKVILLE, MD , June 14, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Jun 14, 2024
RNS Number : 0511S MaxCyte, Inc. 12 June 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Results of AGM   Rockville, Maryland -   June 12 ,   2024:   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Jun 12, 2024
RNS Number : 9400R MaxCyte, Inc. 11 June 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   PDMR Dealing   ROCKVILLE, MD , June 12, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
Jun 11, 2024
RNS Number : 9173Q MaxCyte, Inc. 03 June 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights and Block Listing Return   ROCKVILLE, MD , June 3, 2024 :   MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT),   a leading, cell-engineering focused company providing enabling platform
Jun 03, 2024